The job
Losing fat while holding muscle on GLP-1 or tirzepatide is a two-part job: enough high-quality protein when appetite is gone, plus resistance training. Published incretin trials often report lean tissue as about 20–40% of weight lost — a literature range, not your forecast. The 2025 joint advisory from ACLM, ASN, the Obesity Medicine Association, and The Obesity Society puts 1.2–1.6 g/kg protein and structured strength work on the same list. Protein without training is not a lock-muscle protocol. PivotOrder prints this week’s working protein floor and three leucine hits so the plate still has a number when hunger is off. It does not measure muscle and does not guarantee preserved muscle.
Open the guide →
The number
During GLP-1 or tirzepatide weight loss, the 2025 joint advisory from ACLM, ASN, the Obesity Medicine Association, and The Obesity Society discusses a protein target of 1.2–1.6 g/kg/day. That is a published band, not a PivotOrder invention. Other expert groups have used 1.2–1.5 g/kg. Older adults may need a higher per-meal dose to trigger synthesis. If a clinician already set a gram cap — especially in kidney disease — use that number. PivotOrder prints both ends of the 1.2–1.6 band on the weight you enter, then sets a working floor inside the band from drug, dose week, and appetite. It does not guarantee preserved muscle. Week number alone does not invent a new clinical threshold.
Open the guide →
The plate
On GLP-1 or tirzepatide, the eating question is not “what is healthy” — it is “what still fits.” Appetite and stomach volume both drop, so the day has to be built protein-first and volume-last: anchor each eating occasion on a dense protein that clears roughly 2.5–3 g leucine (the card’s working number is 2.7 g), add vegetables and fibre only after that anchor is in, and keep a cold sip option for the meal that fails. Three anchored occasions usually land an adult inside the 1.2–1.6 g/kg/day protein band the 2025 joint advisory from ACLM, ASN, the Obesity Medicine Association, and The Obesity Society discusses during weight reduction. Eating this way is not a muscle-preservation guarantee — protein is paired with resistance training in that advisory, and neither is measured by an app.
Open the guide →
Bad weeks
Nausea is the most common reason a protein target collapses on GLP-1 or tirzepatide, and it usually peaks in the days after a dose increase. The foods that survive it share a profile: cold or room temperature, low aroma, low fat, smooth texture, and small volume. In practice that means strained or Greek yogurt, cottage cheese blended smooth, kefir, milk, soft or hard-boiled eggs, silken tofu, and cold poached chicken or fish — eaten in smaller, more frequent portions rather than as a plate. One cold dairy-based hit on a bad day still clears a ~2.5–3 g leucine check, which is the whole point of having a floor instead of a meal plan — a floor is a job you can still do badly and not a muscle-preservation guarantee. If you cannot keep fluids down, or nausea comes with vomiting that will not stop, that is the prescribing clinician — not a food swap.
Open the guide →
The shake question
No — a protein shake is not required on GLP-1 or tirzepatide, and PivotOrder does not sell one. What the 2025 joint advisory discusses is adequate protein (a band of 1.2–1.6 g/kg/day during weight reduction) paired with resistance training. It does not specify a delivery format. A shake is simply one low-volume way to hit that band, and it earns its place on exactly one criterion: whether you can reach the floor without it. If strained yogurt, cottage cheese, milk, eggs, and cold chicken get you there, a powder adds cost and nothing else. If solids genuinely will not go down for days at a time, a shake — or plain dairy blended into a drink — is a reasonable tool rather than a moral failure. Either way, it is not a muscle-preservation guarantee.
Open the guide →
The other half
The 2025 joint advisory from ACLM, ASN, the Obesity Medicine Association, and The Obesity Society does not recommend protein on its own. It pairs a protein band of 1.2–1.6 g/kg/day with resistance training, and states plainly that raising protein alone is likely inadequate to support muscle during weight reduction. That is the uncomfortable part of this product: PivotOrder prints the protein half and cannot do the other half for you. General public-health guidance has long been muscle-strengthening work on two or more days per week covering all the major muscle groups, which is a far lower bar than most people assume — two honest sessions a week, not a training programme. Doing both halves is still not a muscle-preservation guarantee, and nothing here is exercise prescription. If you have cardiac, joint, or other conditions, clearance comes from your clinician first.
Open the guide →
The scare
People on Ozempic, Wegovy, Mounjaro, or Zepbound often watch the scale fall and still feel softer — arms, face, grip. Registration-trial DXA and later reviews show lean tissue can be a large share of incretin weight loss. Published figures often land around 20–40% of weight lost, with trial-to-trial spread (STEP 1 DXA analyses have been read near the high end; SURMOUNT-1 DXA nearer ~25%). That is a published range across studies — not your forecast. It is not your personal kilogram of muscle, not a photo diagnosis, and not a PivotOrder scan. Lean mass on DXA is not the same as skeletal muscle. The useful response is still the 2025 standard of care: adequate protein plus resistance training — executed on weeks when appetite is gone. We do not guarantee preserved muscle.
Open the guide →
Dual agonist
Tirzepatide (Mounjaro for type 2 diabetes labeling; Zepbound for obesity labeling in the US) is a dual GIP/GLP-1 receptor agonist. Appetite can fall hard. The 2025 joint advisory still discusses 1.2–1.6 g/kg protein during GLP-1–class weight loss, paired with resistance training. PivotOrder treats tirzepatide as the same protein job as semaglutide: print a working floor inside that band from weight, dose week, and appetite. Dual-agonist labeling can bump the working number inside the band — it does not invent a new medical threshold and does not guarantee preserved muscle. Lean share in SURMOUNT-1 DXA work has been reported near ~25% of lost weight in that analysis — literature, not your arms.
Open the guide →
Not a calorie app
Calorie apps excel at energy accounting. On GLP-1 or tirzepatide therapy the harder failure mode is different: total food noise drops, plates shrink, and absolute protein grams fall even when protein percent of calories looks fine. The 2025 joint advisory puts adequate protein and resistance training on the standard-of-care list for people using these medicines for obesity care. PivotOrder is a weekly protein-floor card — g/day, g/kg inside 1.2–1.6, three leucine hits — not a running calorie total, not photo food OCR, and not a muscle-preservation guarantee. If your only tool is “eat less,” lean tissue can leave with the scale.
Open the guide →
Why subscribe
Your first week is free — the full daily loop, no card required. Next week the inputs often move: dose week advances, nausea flips you to sips, or body weight drops and g/kg math changes inside the 1.2–1.6 published band. After that, daily support keeps today’s plan, the log, and the weekly review current — CA$15/month or CA$120/year. Cancel anytime. It is not more recipes. It does not guarantee preserved muscle.
Open the guide →
The meal mechanic
Muscle protein synthesis research often treats roughly 2.5–3 g leucine in a meal as a practical trigger threshold for adults — a literature heuristic from dose–response work (for example Moore et al., Am J Clin Nutr 2009; Layman et al., Am J Clin Nutr 2015), not a PivotOrder lab assay. PivotOrder uses 2.7 g as the working per-meal check and asks for three hits in the week when appetite is off on GLP-1 or tirzepatide. That sits beside the daily 1.2–1.6 g/kg protein band from the 2025 advisory. Food first. We do not sell the powder. Hitting leucine does not guarantee preserved muscle; missing it is still a useful red flag when the drug has shut hunger down.
Open the guide →
